The landscape of drug safety testing is undergoing a profound transformation, marked by the rapid ascent of New Approach Methodologies (NAMs). While recent regulatory milestones, such as the FDA Modernization Act 2.0, might suggest an overnight shift, the reality is a culmination of over a decade of scientific innovation, concerted multi-stakeholder collaboration, and evolving regulatory frameworks. This strategic evolution is particularly evident in cardiac safety assessment, where human-relevant functional NAMs are now demonstrating unprecedented predictive power, promising to revolutionize drug development and enhance patient protection.
The Genesis of a Paradigm Shift: Challenging Traditional Safety Models
For decades, preclinical drug safety assessment relied heavily on animal models. While indispensable in their time, these traditional assays often presented significant limitations, particularly in their ability to accurately predict human physiological responses. The inherent species differences between animals and humans frequently led to discrepancies, resulting in a high attrition rate of promising drug candidates in late-stage clinical trials due to unforeseen safety liabilities. Cardiac toxicity, specifically drug-induced proarrhythmia (the propensity of a drug to cause potentially fatal heart rhythm disturbances like torsades de pointes), emerged as a particularly stubborn challenge. Despite rigorous animal testing and in vitro assays like hERG channel block, drugs continued to fail in clinical trials or, in rare but tragic instances, reach the market only to be withdrawn due to severe cardiac side effects. This persistent gap between preclinical prediction and clinical reality underscored an urgent need for more human-relevant, mechanism-based approaches.
Recognizing these systemic challenges, global initiatives began to emerge in the early to mid-2010s, laying the scientific groundwork for what would become the NAM movement. Programs such as Tox21 (a collaboration between EPA, NIH, and FDA) and ToxCast (EPA) pioneered the use of high-throughput in vitro screening technologies to evaluate the toxicity of thousands of chemicals and drugs. These initiatives aimed to identify molecular pathways and cellular responses indicative of toxicity, moving beyond traditional animal studies to predict human health effects more efficiently and accurately. Their fundamental principle was clear: human-relevant biological systems, when interrogated with sophisticated mechanistic assays, could provide predictive power equal to or even exceeding that of conventional animal models.
CiPA: A Blueprint for Cardiac Safety Innovation
Among these pioneering efforts, the Comprehensive in vitro Proarrhythmia Assay (CiPA) initiative stands out as a critical accelerator for cardiac safety NAMs. Launched in 2013 as a public-private partnership involving regulatory agencies (FDA, EMA, PMDA), pharmaceutical companies, academic researchers, and technology developers, CiPA aimed to modernize the assessment of proarrhythmic risk. Prior to CiPA, the primary nonclinical assay for cardiac risk was the hERG (human Ether-à-go-go-Related Gene) assay, which measures a drug’s potential to block a specific potassium ion channel in heart cells. While useful, hERG block alone was an overly sensitive predictor, leading to the shelving of many safe and effective drugs or, conversely, failing to catch all proarrhythmic compounds.
CiPA proposed a multi-pronged approach that integrated:
- Multi-ion channel pharmacology: Assessing drug effects on several key cardiac ion channels (e.g., hERG, Nav1.5, Cav1.2).
- Human iPSC-derived cardiomyocyte (hiPSC-CM) assays: Utilizing human induced pluripotent stem cell-derived cardiomyocytes, which recapitulate many features of native human heart cells, to measure functional electrophysiological changes.
- Computational modeling: Integrating in vitro data into sophisticated computer models of human ventricular action potentials to predict arrhythmia risk.
The core of CiPA’s success lay in the rigorous validation of hiPSC-CM assays, particularly those employing Microelectrode Array (MEA) technology. Two landmark multicenter CiPA studies, involving numerous laboratories worldwide, conclusively demonstrated that hiPSC-CM MEA assays could reliably detect delayed repolarization and arrhythmia-like events, directly correlating with the risk of torsades de pointes. This empirical validation was instrumental in building confidence across the scientific and regulatory communities. The findings from CiPA directly informed the 2022 update to the International Council for Harmonisation (ICH) E14/S7B Questions & Answers guidance document, which officially recognized hiPSC-CM data as valuable supportive evidence for proarrhythmic risk assessment. This marked a significant global regulatory endorsement, signifying a move away from sole reliance on in vivo and limited in vitro data.
The FDA Modernization Act 2.0: Codifying a Decade of Progress
The passage of the FDA Modernization Act 2.0 in December 2022 was widely celebrated as a pivotal moment for NAMs. This legislation removed the statutory requirement for animal testing in drug development for the first time in over 80 years, explicitly allowing non-animal methods to be used in regulatory submissions. While perceived by some as a sudden, groundbreaking shift, this legislative change was, in essence, a formal acknowledgement of the scientific, technical, and regulatory progress that had been accumulating for over a decade. It didn’t mandate the replacement of animal testing overnight but rather provided the legal framework and regulatory flexibility for the adoption of validated NAMs.
The Act signaled a clear intent from the highest levels of government to support and accelerate the integration of alternative approaches. For safety leaders within pharmaceutical organizations, the question transitioned from "if" to "which" NAM platforms are sufficiently validated, trusted, and ready for regulatory-facing applications. The FDA, through initiatives like its Innovative Science and Technology Approaches for New Drugs (ISTAND) Pilot Program, had already been proactively creating pathways for engagement between regulators, industry, and technology developers. ISTAND provides a framework for discussing and evaluating novel drug development tools, including NAMs, establishing "fit-for-purpose" evidence requirements and fostering alignment on their appropriate use in regulatory submissions. This program has been crucial in demystifying the regulatory acceptance process and building mutual confidence in new technologies.
Functional NAMs in Action: The Power of iPSC-Derived Cardiomyocytes and MEA Technology
Cardiac safety stands as a premier example of how regulatory-ready NAMs are achieving tangible results. The key to this success lies in the ability to utilize functional, human-derived physiology to make more informed safety decisions. Human iPSC-derived cardiomyocytes (hiPSC-CMs) combined with Microelectrode Array (MEA) technology have emerged as a central pillar in this evolution.
MEA platforms, such as Axion BioSystems’ Maestro MEA, enable continuous, noninvasive monitoring of cardiac electrophysiology in vitro. These systems measure the electrical activity of a monolayer of hiPSC-CMs, providing real-time data on parameters like beat rate, field potential duration (FPD, a surrogate for QT interval), and indicators of arrhythmia. This functional data is not only physiologically relevant, closely mimicking human cardiac responses, but also operationally practical for the high-throughput demands of pharmaceutical and Contract Research Organization (CRO) environments. The ability to observe subtle changes in cardiac rhythm and conduction patterns induced by drug candidates offers a significantly more nuanced and predictive assessment of proarrhythmic risk compared to single-channel assays or even many animal models.
A recent regulatory milestone highlights this progress: the acceptance of a Letter of Intent from Axion BioSystems for a human iPSC-derived cardiomyocyte MEA assay into the FDA’s ISTAND program. This achievement is not merely a corporate success but reflects years of sustained investment across the entire drug discovery ecosystem—from academic research into stem cell biology to industrial development of MEA platforms and rigorous regulatory science. It underscores the growing confidence in these functional assays to directly measure human cardiac electrophysiology in vitro and support regulated safety workflows. This formal engagement through ISTAND provides a structured dialogue with the FDA, paving the way for broader regulatory acceptance and integration of this specific NAM into drug development pathways.
Evidence of Accelerated Adoption and Superior Predictive Performance
The voluntary adoption of hiPSC-CM data by drug sponsors, even before it became a formal requirement, is a compelling indicator of its value. A 2025 study authored by FDA scientists revealed a consistent increase in Investigational New Drug (IND) applications submitted with iPSC-CM data over the past decade. Notably, between 2020 and 2023, the number of submissions including hiPSC-CM MEA assays doubled compared to the total number submitted prior to 2020. This acceleration reflects a growing confidence among pharmaceutical companies in the predictive power and regulatory utility of these approaches.
Further reinforcing this trend, a new paper currently under review provides even stronger evidence. This research demonstrates that hiPSC-CM data exhibit strong concordance with clinical QT outcomes and show higher predictive performance than traditionally required methods, including hERG assays, multi-ion channel approaches, and even traditional animal QT studies. Crucially, the study also illustrates that using hiPSC-CM data in combination with other in vitro assays significantly reduces nonclinical QT false negatives. This combined approach demonstrated predictive value comparable to multiple animal studies, opening the door for the potential replacement of additional animal studies in the future. The implications are profound: enhanced patient safety through better prediction of cardiac risk, faster drug development cycles by reducing late-stage attrition, and a significant reduction in animal use.
The market response also speaks volumes. At least 16 Contract Research Organizations (CROs) worldwide now offer CiPA-style hiPSC-CM assays as a standard service, frequently utilizing platforms like the Maestro Pro MEA system. This widespread commercial availability underscores not only the scientific credibility of these assays but also their operational practicality and demand from the pharmaceutical industry. The voluntary uptake by sponsors and CROs demonstrates that these assays are delivering tangible value, empowering development teams to reduce uncertainty and make better-informed safety decisions earlier in the drug discovery process.
Ensuring Consistency: The AIMS Initiative and Future Standards
As functional NAMs transition from validation into broader regulatory use, ensuring consistency across different laboratories and experiments becomes paramount. Variability in model performance, assay protocols, and data interpretation could quickly erode confidence and hinder widespread adoption. To address this critical challenge, the Axion iPSC Model Standards (AIMS) initiative was launched. This collaborative effort brings together leaders in the safety field—from pharmaceutical companies, CROs, and academic institutions—to define meaningful functional standards for hiPSC-CM MEA assays.
The goal of AIMS is to establish clear benchmarks for baseline electrophysiological performance, acceptable levels of variability, and expected responses to well-characterized reference compounds. By setting these standards, AIMS aims to:
- Enhance reproducibility: Ensure that results obtained in one laboratory can be reliably replicated in another.
- Facilitate data comparability: Allow for robust comparison of data generated across different studies and institutions.
- Build regulatory confidence: Provide a framework that assures regulators of the quality and consistency of NAM data.
- Support future regulatory frameworks: Lay the groundwork for integrating these standardized assays into official guidance and requirements.
These collective efforts—from the scientific rigor of CiPA, to the voluntary inclusion of hiPSC-CM data in IND submissions, to the regulatory engagement facilitated by ISTAND, and now the standardization drive of AIMS—illustrate how cardiac safety has become a benchmark for NAM maturity. It showcases a model for adoption built on robust science, collaborative regulatory engagement, and an unwavering commitment to standards grounded in human-relevant physiology.
A Managed Transition: Opportunity and Responsibility for Safety Leaders
For safety leaders across the pharmaceutical industry, the current inflection point for NAMs presents both immense opportunity and significant responsibility. The opportunity lies in leveraging advanced tools that provide earlier, more accurate, and human-relevant insights into cardiac risk, thereby streamlining drug development, reducing costs, and ultimately bringing safer and more effective medicines to patients faster. The responsibility, however, is to implement these sophisticated methodologies thoughtfully, ensuring they integrate seamlessly into existing decision-making processes without introducing undue uncertainty or complexity.
The true risk in today’s evolving landscape is not the adoption of new technologies, but rather the continued reliance on outdated approaches that have not kept pace with the scientific advancements in human cardiac biology. The narrative of a "sudden" NAM shift is misleading; the tools now entering routine safety workflows are the product of years of meticulous validation, cross-sector collaboration, and substantial investment in regulatory science. Platforms that combine proven performance with proactive regulatory engagement and a steadfast commitment to standardization offer a clear path forward—one that is evolutionary, rather than disruptive. This managed transition empowers safety organizations to embrace innovation confidently, ensuring that the next generation of therapeutics is developed with an unparalleled understanding of human cardiac safety.
Mike Clements, PhD, SVP Scientific Partnerships & Strategy at Axion BioSystems, whose pioneering 2014 research first demonstrated the potential of Maestro MEA with stem cell-derived cardiomyocytes for preclinical cardiac safety screening, emphasizes this point. His work, which later helped inform the CiPA initiative, underscores the long-term commitment and scientific rigor that underpins the current widespread acceptance. As the editor of "Stem Cell-Derived Models in Toxicology," a comprehensive resource on next-generation in vitro toxicology platforms, and former president of the stem cells specialty section of the Society of Toxicology, Dr. Clements’ insights highlight the deep scientific roots from which this revolution has grown. The move towards functional NAMs is not a leap of faith but a meticulously engineered progression, promising a safer and more efficient future for drug development.
Leave a Reply